title: Stability of laser epithelial keratomileusis with and without mitomycin C performed to correct myopia in thin corneas: a 15-month follow-up.
abstract: OBJECTIVE
  To study the stability of the refraction 15 months after myopic laser epithelial keratomileusis (LASEK) performed in thin corneas with and without adjuvant mitomycin C (MMC).
  
  
  METHODS
  Retrospective review.
  
  
  METHODS
  One hundred and thirty-six consecutive eyes that had undergone LASEK to correct their myopia and that had a preoperative central corneal thickness (CCT) of <500 microm at Vissum Madrid, Spain, were included. Intraoperative MMC was applied when the ablation depth exceeded 50 microm (49 eyes). We compared the residual refraction between the three- and 15-month examinations to detect a possible myopic change that would suggest secondary corneal ectasia.
  
  
  RESULTS
  Mean preoperative CCT +/- standard deviation (SD) was 484.4 +/- 11.8 microm (range, 440 to 499 microm). Mean CCT +/- SD three months after surgery was 417.9 +/- 32.1 microm (range, 339 to 473 microm). Mean preoperative spherical refraction +/- SD was -3.49 +/- 2.10 diopters (D). Mean preoperative cylinder +/- SD was -0.87 +/- 1.20 D. The mean residual sphere +/- SD was 0.15 +/- 0.40 D three months after surgery and 0.11 +/- 0.60 D 15 months after surgery (P = .45). The mean cylinder +/- SD was -0.13 +/- 0.30 D and -0.25 +/- 0.50 D, respectively (P = .06). Both the uncorrected visual acuity (UCVA) and the best-spectacle corrected visual acuity (BSCVA) showed statistically significant improvement on the 15-month examination (P = .01 and P = .0001, respectively). When analyzed separately, the subgroup treated with intraoperative MMC also showed stability of the refraction and a statistically significant improvement both in UCVA and in BSCVA. Topography showed no signs of ectasia in any case.
  
  
  CONCLUSIONS
  Myopic LASEK performed on thin corneas, regardless of the use of intraoperative MMC, seems to obtain stable refractive results, with no sign of ectasia during a 15-month follow-up.
authors.affiliation: Vissum Madrid, Madrid, Spain. lbenito@vissum.com
authors.forename: Laura
authors.initials: L
authors.lastname: de Benito-Llopis
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Teus
authors.forename: Jose M
authors.initials: JM
authors.lastname: Sánchez-Pina
authors.forename: Irene
authors.initials: I
authors.lastname: Fuentes
mesh_terms: D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003315:Cornea / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D049008:Keratectomy, Subepithelial, Laser-Assisted / Q000379:methods*; D054018:Lasers, Excimer; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D009216:Myopia / Q000188:drug therapy* / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D000477:Alkylating Agents; D016685:Mitomycin